InflaRx N.V. (IFRX) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 11.9% versus a loss of 30.4%. Over five years, IFRX leads with a -55.3% price change compared with -94.7% for RNAC. InflaRx N.V. is the larger company by market cap ($194.5 million vs $189.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | RNAC |
|---|---|---|
| Share price | $1.32 | $6.27 |
| Market cap | $194.53M | $189.70M |
| 1-day change | -8.33% | -4.71% |
| YTD return | +30.69% | -13.04% |
| 1-year return | +11.86% | -30.41% |
| 5-year return | -55.25% | -94.71% |
| EPS (TTM) | $-0.58 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.80M |
| Revenue growth (YoY) | — | -92.81% |
| Net income (latest FY) | — | $-130.30M |
| Operating margin | — | -5127.10% |
| Net margin | — | -4658.63% |
| 52-week high | $2.95 | $11.00 |
| 52-week low | $0.798 | $5.60 |
| Distance from 52-week high | -55.24% | -43.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +481.06% | +437.00% |
| Average volume | 768.60K | 131.23K |
| Shares outstanding | 147.37M | 30.26M |
| Employees | 65 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed RNAC by 42.3 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
IFRX vs RNAC FAQ
Which is bigger, InflaRx N.V. or Cartesian Therapeutics?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $194.53M compared with $189.70M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, IFRX or RNAC?
IFRX returned +11.86% over the past 12 months, compared with -30.41% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.